Other research analysts have also issued research reports about the stock. Jefferies Financial Group upped their price objective on shares of Quotient from $11.00 to $13.50 and gave the company a “buy” rating in a research note on Tuesday, March 5th. ValuEngine lowered shares of Quotient from a “strong-buy” rating to a “buy” rating in a research note on Friday, April 19th. Finally, Zacks Investment Research upgraded shares of Quotient from a “sell” rating to a “hold” rating in a research note on Wednesday, May 8th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. Quotient presently has an average rating of “Hold” and a consensus target price of $11.75.
Quotient stock opened at $9.26 on Tuesday. The company has a market capitalization of $544.96 million, a price-to-earnings ratio of -4.58 and a beta of 1.25. The company has a current ratio of 6.87, a quick ratio of 6.05 and a debt-to-equity ratio of 4.95. Quotient has a twelve month low of $4.54 and a twelve month high of $11.15.
Several institutional investors and hedge funds have recently made changes to their positions in QTNT. Granite Point Capital Management L.P. acquired a new position in shares of Quotient during the 4th quarter worth $1,346,000. Victory Capital Management Inc. purchased a new stake in Quotient in the 4th quarter worth about $1,224,000. Quantum Capital Management increased its holdings in Quotient by 42.3% in the 4th quarter. Quantum Capital Management now owns 385,558 shares of the company’s stock worth $2,360,000 after acquiring an additional 114,597 shares during the last quarter. Monashee Investment Management LLC purchased a new stake in Quotient in the 4th quarter worth about $1,530,000. Finally, Castleark Management LLC purchased a new stake in Quotient in the 4th quarter worth about $462,000. Institutional investors own 66.32% of the company’s stock.
Quotient Company Profile
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening.
Recommended Story: Why is a lock-up period needed for an IPO?
Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.